ClinicalTrials.gg
CompletedNCT03491553Updated Aug 19, 2021Results posted

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

A Phase 2 interventional study of Selgantolimod and Placebo in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-08-19.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Hepatitis B, Chronic by Gilead Sciences — none open to participants now, 2 under way, 1 of them phase 3. Hepatitis B, Chronic · Gilead Sciences.

Enrollment
25th of 29
48 · median 112
Started
2018
with 2 others
Phase 2
15 of 34
none open now
Registered
31st of 34
by date

Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 25th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 31st registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 34 studies in Hepatitis B, Chronic by Gilead Sciences is open now. The open studies under Hepatitis B, Chronic, anywhere →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies in Hepatitis B, Chronic by Gilead Sciences as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have the ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Adult males and non-pregnant, non-lactating females
  • Documented evidence of chronic infection with detectable hepatitis B surface antigen (HBsAg) levels
  • On commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening
  • HBV Deoxyribonucleic acid (DNA) ≤ 20 IU/mL for 6 or more months prior to screening
  • Screening (ECG) without abnormalities

Key Exclusion Criteria:

  • Extensive bridging fibrosis or cirrhosis
  • Adults meeting any of the protocol defined exclusionary laboratory parameters at screening:

    • (ALT) > 3x (ULN)
    • (INR) > ULN unless the adult is stable on an anticoagulant regimen
    • Albumin \< 3.5 g/dL
    • Direct > 1.5x ULN
    • Count \< 100,000/uL
    • Estimated \< 60 mL/min (using the Cockcroft-Gault method)
  • Co-infection with , virus or hepatitis D virus
  • Prior history of hepatocellular carcinoma (HCC) or screening alpha-fetoprotein ≥ 50 ng/mL without imaging
  • Diagnosis of disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe , hemoglobinopathy, retinal disease, or are .
  • Chronic liver disease of a non-HBV etiology, except for non-alcoholic fatty liver disease
  • Received solid organ or bone marrow transplant
  • Received prolonged therapy with immunomodulators or biologics within 3 months of screening
  • Use of another agent within 90 days of screening, unless allowed by the Sponsor

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Selgantolimod 3 mg: HBeAg-positive CHB Participants

    Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.

    Drug: Selgantolimod · Drug: Hepatitis B virus (HBV) OAV Therapy

  • Experimental
    Selgantolimod 3 mg: HBeAg-negative CHB Participants

    Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Selgantolimod · Drug: Hepatitis B virus (HBV) OAV Therapy

  • Experimental
    Selgantolimod 1.5 mg: HBeAg-positive CHB Participants

    Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Selgantolimod · Drug: Placebo · Drug: Hepatitis B virus (HBV) OAV Therapy

  • Experimental
    Selgantolimod 1.5 mg: HBeAg-negative CHB Participants

    Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Selgantolimod · Drug: Placebo · Drug: Hepatitis B virus (HBV) OAV Therapy

  • Experimental
    Placebo: HBeAg-positive CHB Participants

    Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Placebo · Drug: Hepatitis B virus (HBV) OAV Therapy

  • Experimental
    Placebo: HBeAg-negative CHB Participants

    Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.

    Drug: Placebo · Drug: Hepatitis B virus (HBV) OAV Therapy

Interventions

  • Tablet(s) administered orally once weekly

    Also known as: GS-9688

  • DrugPlacebo

    Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly

  • DrugHepatitis B virusStudies of Hepatitis B virusHepatitis B virus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Commercially available HBV OAV therapy could include one of the following: Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4

    Time frame: Week 4

  2. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8

    Time frame: Week 8

  3. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12

    Time frame: Week 12

  4. Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48

    Time frame: Week 48

  5. Change From Baseline in Serum qHBsAg at Week 4

    Time frame: Baseline, Week 4

  6. Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 8

    Time frame: Baseline, Week 8

  7. Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 12

    Time frame: Baseline, Week 12

  8. Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 24

    Time frame: Baseline, Week 24

  9. Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 48

    Time frame: Baseline, Week 48

  10. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

    Time frame: Week 12

  11. Percentage of Participants With HBsAg Loss at Week 24

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

    Time frame: Week 24

  12. Percentage of Participants With HBsAg Loss at Week 48

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

    Time frame: Week 48

  13. Percentage of Participants With HBeAg Loss and Seroconversion at Week 12

    HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.

    Time frame: Week 12

  14. Percentage of Participants With HBeAg Loss and Seroconversion at Week 24

    HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.

    Time frame: Week 24

  15. Percentage of Participants With HBeAg Loss and Seroconversion at Week 48

    HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as hepatitis B e antibody (HBeAb) test changing from negative or missing at baseline to positive at a postbaseline visit.

    Time frame: Week 48

  16. Percentage of Participants With Virologic Breakthrough

    Virologic breakthrough was defined as having two consecutive visits of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 69 IU/mL.

    Time frame: Baseline up to Week 48

  17. Percentage of Participants With Drug Resistance Mutations

    The criteria for a drug resistance mutation was having two consecutive visits of HBV DNA ≥ 69 IU/mL.

    Time frame: Baseline up to Week 48

07

Results

Posted Apr 1, 2020

Participant flow

Participants were enrolled at study sites in New Zealand and the United States. The first participant was screened on 6 April 2018. The last study visit occurred on 10 August 2020.

Main Study (Up to Week 48)
Participant flow — Main Study (Up to Week 48)
MilestoneSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Started910101054
Completed8910954
Not completed110100
Withdrew: Adverse event000100
Withdrew: Withdrew consent110000
TFFU (Week 49 up to Additional 48 Weeks)
Participant flow — TFFU (Week 49 up to Additional 48 Weeks)
MilestoneSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Started010000
Completed010000
Not completed000000

Outcome measures

PrimaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24
Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 240 (0.0 to 33.6)0 (0.0 to 30.8)0 (0.0 to 30.8)10.0 (0.3 to 44.5)0 (0.0 to 52.2)0 (0.0 to 60.2)
Statistical analysis
  • Selgantolimod 3 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 3 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 10.0 · 95% CI -47.2 to 47.1The 2-sided 95% CI for the percentage difference by HBeAg status was constructed based on the standardized statistic and inverting two 1-sided tests.
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4
Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 40 (0.0 to 33.6)0 (0.0 to 30.8)0 (0.0 to 30.8)0 (0.0 to 30.8)0 (0.0 to 52.2)0 (0.0 to 60.2)
Statistical analysis
  • Selgantolimod 3 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 3 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8
Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 80 (0.0 to 33.6)0 (0.0 to 30.8)0 (0.0 to 30.8)0 (0.0 to 30.8)0 (0.0 to 52.2)0 (0.0 to 60.2)
Statistical analysis
  • Selgantolimod 3 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 3 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 120 (0.0 to 33.6)0 (0.0 to 30.8)0 (0.0 to 30.8)0 (0.0 to 30.8)0 (0.0 to 52.2)0 (0.0 to 60.2)
Statistical analysis
  • Selgantolimod 3 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 3 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
SecondaryPercentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 480 (0.0 to 33.6)0 (0.0 to 30.8)0 (0.0 to 30.8)10.0 (0.3 to 44.5)0 (0.0 to 52.2)0 (0.0 to 60.2)
Statistical analysis
  • Selgantolimod 3 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 3 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-positive CHB Participants vs Placebo: HBeAg-positive CHB Participants · Percentage difference: 0.0
  • Selgantolimod 1.5 mg: HBeAg-negative CHB Participants vs Placebo: HBeAg-negative CHB Participants · Percentage difference: 10.0 · 95% CI -47.2 to 47.1The 2-sided 95% CI for the percentage difference by HBeAg status was constructed based on the standardized statistic and inverting two 1-sided tests.
SecondaryChange From Baseline in Serum qHBsAg at Week 4
Time frame:
Baseline, Week 4
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg at Week 4
log10 IU/mLSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Change From Baseline in Serum qHBsAg at Week 40.02 ± 0.047-0.07 ± 0.1100.00 ± 0.070-0.01 ± 0.127-0.02 ± 0.034-0.03 ± 0.058
SecondaryChange From Baseline in Serum qHBsAg (log10 IU/mL) at Week 8
Time frame:
Baseline, Week 8
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 8
log10 IU/mLSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 80.00 ± 0.051-0.05 ± 0.117-0.01 ± 0.041-0.04 ± 0.1190.02 ± 0.041-0.03 ± 0.061
SecondaryChange From Baseline in Serum qHBsAg (log10 IU/mL) at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 12
log10 IU/mLSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 12-0.01 ± 0.059-0.05 ± 0.1170.00 ± 0.050-0.04 ± 0.1150.05 ± 0.0340.00 ± 0.048
SecondaryChange From Baseline in Serum qHBsAg (log10 IU/mL) at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 24
log10 IU/mLSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 240.01 ± 0.059-0.05 ± 0.136-0.05 ± 0.059-0.16 ± 0.460-0.02 ± 0.048-0.01 ± 0.066
SecondaryChange From Baseline in Serum qHBsAg (log10 IU/mL) at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · log10 IU/mL
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 48
log10 IU/mLSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Change From Baseline in Serum qHBsAg (log10 IU/mL) at Week 48-0.01 ± 0.073-0.05 ± 0.145-0.07 ± 0.110-0.17 ± 0.5230.00 ± 0.049-0.05 ± 0.050
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12010.00000
SecondaryPercentage of Participants With HBsAg Loss at Week 24

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 24
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With HBsAg Loss at Week 24010.00000
SecondaryPercentage of Participants With HBsAg Loss at Week 48

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 48
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Percentage of Participants With HBsAg Loss at Week 48010.0010.000
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 12

HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 12
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-positive CHB Participants
HBeAg Loss010.00
HBeAg Loss and Seroconversion000
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 24

HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 24
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-positive CHB Participants
HBeAg Loss010.00
HBeAg Loss and Seroconversion000
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 48

HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as hepatitis B e antibody (HBeAb) test changing from negative or missing at baseline to positive at a postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 48
percentage of participantsSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-positive CHB Participants
HBeAg Loss22.210.00
HBeAg Loss and Seroconversion11.100
SecondaryPercentage of Participants With Virologic Breakthrough

Virologic breakthrough was defined as having two consecutive visits of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 69 IU/mL.

Time frame:
Baseline up to Week 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Drug Resistance Mutations

The criteria for a drug resistance mutation was having two consecutive visits of HBV DNA ≥ 69 IU/mL.

Time frame:
Baseline up to Week 48

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events: First dose date up to last dose date (maximum duration: 24 Weeks) plus 30 days; All Cause Mortality: Randomization up to 28 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selgantolimod 3 mg: HBeAg-positive CHB Participants0/9 (0%)1/9 (11.1%)9/9 (100%)
Selgantolimod 3 mg: HBeAg-negative CHB Participants0/10 (0%)0/10 (0%)10/10 (100%)
Selgantolimod 1.5 mg: HBeAg-positive CHB Participants0/10 (0%)1/10 (10%)8/10 (80%)
Selgantolimod 1.5 mg: HBeAg-negative CHB Participants0/10 (0%)2/10 (20%)10/10 (100%)
Placebo: HBeAg-positive CHB Participants0/5 (0%)0/5 (0%)5/5 (100%)
Placebo: HBeAg-negative CHB Participants0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
Perineal abscessInfections and infestations1/90/100/100/100/50/4
Atrial fibrillationCardiac disorders0/90/100/101/100/50/4
IridocyclitisEye disorders0/90/100/101/100/50/4
Abdominal pain lowerGastrointestinal disorders0/90/101/100/100/50/4
Most frequent other events
Showing 10 of 90
Most frequent other events
EventSelgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB Participants
NauseaGastrointestinal disorders6/95/103/104/100/50/4
Dry eyeEye disorders0/90/100/100/100/52/4
FatigueGeneral disorders0/95/101/102/100/51/4
HeadacheNervous system disorders2/91/102/103/102/52/4
Upper respiratory tract infectionInfections and infestations1/93/101/104/102/51/4
Back painMusculoskeletal and connective tissue disorders2/92/102/100/102/50/4
MyalgiaMusculoskeletal and connective tissue disorders3/90/100/102/100/50/4
DiarrhoeaGastrointestinal disorders1/91/100/103/101/50/4
VomitingGastrointestinal disorders2/93/103/101/100/50/4
TinnitusEar and labyrinth disorders0/90/100/100/100/51/4

Baseline characteristics

The Safety Analysis Set included all randomized participants who took at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Selgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB ParticipantsTotal
Mean43 ± 7.846 ± 10.143 ± 5.653 ± 6.843 ± 7.957 ± 10.547 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Selgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB ParticipantsTotal
Female23311212
Male77794236
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB ParticipantsTotal
Hispanic or Latino0000000
Not Hispanic or Latino91010105448
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Selgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB ParticipantsTotal
Asian56573228
Black or African American0301015
Native Hawaiian or Pacific Islander41411112
White0010001
Other0001102
Region of Enrollment
Region of Enrollment(Participants)Selgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB ParticipantsTotal
United States17160217
New Zealand83945231
Hepatitis B Surface Antigen (HBsAg)
Hepatitis B Surface Antigen (HBsAg)(log10 IU/mL)Selgantolimod 3 mg: HBeAg-positive CHB ParticipantsSelgantolimod 3 mg: HBeAg-negative CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-positive CHB ParticipantsSelgantolimod 1.5 mg: HBeAg-negative CHB ParticipantsPlacebo: HBeAg-positive CHB ParticipantsPlacebo: HBeAg-negative CHB ParticipantsTotal
Mean3.4 ± 0.572.6 ± 1.583.4 ± 0.621.7 ± 1.103.3 ± 0.463.2 ± 0.422.9 ± 1.14
08

Study locations

2 sites
  • University of Maryland, Institute of Human Virology
    Baltimore, Maryland 21201, United States
  • Auckland Clinical Studies Limited
    Auckland, 1010, New Zealand
09

References and documents

Publications

  • Brooks AE, Verdon D, Eom J, Ng J, Steemson H, Lau AH, et al. Peripheral Immune Responses to Toll-Like Receptor 8 Agonist Selgantolimod (GS-9688) in Patients with Chronic Hepatitis B [Poster]. AASLD: The Liver Meeting® 2019; 2019 08-12 November; Boston, MA.
  • Gane E, Zhao Y, Tan SK, Lau AH, Gaggar A, Subramanian M, et al. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study [Poster 697]. AASLD: The Liver Meeting® 2019; 2019 08-12 November; Boston, MA.
  • Chen DY, C. M, Tan SK, Yang JC, Gane EJ, Janssen HLA, et al. Characterization of Cytokine Response to Toll-Like Receptor 8 Agonist Selgantolimod in Viremic and Virally Suppressed Chronic Hepatitis B Patients [Poster 0721]. American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience; 2020 13-16 November.
  • Chen D, Kim S, Brooks A, McDonald C, Yang J, Gaggar A, et al. Potential Biomarkers of Response in Chronic Hepatitis B Patients Who Achieved HBeAg Loss Upon Treatment With Toll-Like Receptor 8 Agonist Selgantolimod [Poster FR1350]. The Digital International Liver Congress (ILC); 2020 27-29 August.
  • Gane E, Dubar PR, Brooks AE, Zhao Y, Tan SK, Lau AH, et al. Efficacy and Safety of 24 Weeks Treatment with Oral TLR8 Agonist Selgantolimod (GS-9688, SLGN) in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study [Presentation]. The Digital International Liver Congress (ILC); 2020 27-29 August.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Mar 2019, 11 months.

Results were first posted in Apr 2020, 1 year after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 11 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2018
First posted
Apr 9, 2018
StartActual
Apr 6, 2018
Primary completionActual
Mar 22, 2019
CompletionActual
Aug 10, 2020
Results first posted
Apr 1, 2020
Last update
Aug 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03491553
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 9, 2018
Start date
Apr 6, 2018
Primary completion
Mar 22, 2019
Completion
Aug 10, 2020
Results posted
Apr 1, 2020
Last update
Aug 19, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selgantolimod

Start the discussion